понедельник, 16 мая 2011 г.

Penn Researchers Demonstrate Ability Of New Therapy To Treat Patients With Severely Elevated Cholesterol Levels

Researchers at the University of Pennsylvania School of Medicine have demonstrated the potential of a new type of therapy for patients who suffer from high cholesterol levels. The findings are in the January 11 issue of the New England Journal of Medicine (NEJM). In this study, patients with homozygous familial hypercholesterolemia (FH), a high-risk condition refractory to conventional therapy, had a remarkable 51% reduction in low-density lipoprotein (LDL) or "bad cholesterol" levels.


"Our study shows that targeted inhibition of the microsomal triglyceride transfer protein (MTP) is highly effective in reducing cholesterol levels in these very high risk patients," stated Daniel J. Rader, MD, Director of Preventive Cardiology and the Clinical and Translational Research Center at Penn, and principal investigator of this study. "Furthermore, there are many other patients who have cholesterol levels that are difficult to treat or who are not tolerant to treatment with statins. New therapies are required for these patients as well, and it is possible that after further research MTP inhibition could eventually be used for such patients."


Genetic defects in MTP lead to profoundly low levels of LDL. Using this information, Bristol-Myers Squibb began to search for inhibitors of this protein and discovered the study drug, originally known as BMS-201038. Bristol-Myers Squibb then donated it to Penn for use in clinical trials in patients with severe cholesterol problems. Rader and his team at Penn designed and carried out the current study in homozygous FH patients with support from the Doris Duke Charitable Foundation. Due to the success in this study, Penn has licensed the drug to Aegerion Pharmaceuticals Inc for further development as AEGR-733.


Patients who suffer from homozygous FH typically respond poorly to standard drug therapy and have a very high risk of premature cardiovascular disease. Homozygous FH is caused by loss-of-function mutations in both alleles of the LDL receptor gene. It is a rare form of hypercholesterolemia affecting approximately one in every million people. Patients with this disorder typically have plasma cholesterol levels of more than 500 mg per deciliter. If untreated, patients develop cardiovascular disease before they are 20-years-old and generally do not live past the age of 30. Because existing cholesterol lowering drugs are relatively ineffective in this patient population, new therapies to reduce LDL levels are needed.


In this study, researchers conducted a dose-escalation study to examine the safety, tolerability and effects on lipid levels of an inhibitor of MTP in six patients with homozygous FH. Patients received the MTP inhibitor at four different doses, each for four weeks, and returned for a final visit after an additional four-week drug washout period. Analysis of lipid levels, safety laboratory analyses, and magnetic resonance imaging of the liver for hepatic fat content were performed throughout the study. All patients tolerated titration to the highest dose studied. In addition to the 51% reduction in LDL cholesterol, treatment at this dose also decreased total cholesterol levels by 58%, triglyceride levels by 65% and apolipoprotein B levels by 56% from baseline. In contrast to statin drugs, which have relatively little effect on cholesterol levels in homozygous FH patients, the MTP inhibitor was shown to reduce the liver's ability to produce LDL. The most notable adverse events in the study were loose stools and elevation of liver transaminase levels and accumulation of hepatic fat in some but not all of the patients studied.















Rader concluded, "Although our study establishes proof of concept, a longer-term study in more patients will be required to determine the benefits and risks of this approach as a potential new therapy for homozygous familial hypercholesterolemia." Marina Cuchel, MD, PhD, a co-investigator in this study at Penn, is now the principal investigator of a Phase III study for this compound in homozygous FH patients that is funded by the U.S. Food and Drug Administration Orphan Drug program and planned for later this year.


Rader points out that this study is a superb example of "translational research" in which discoveries in basic science are "translated" into use in humans for the development of novel therapies. Rader is an internationally recognized leader in translational research in the areas of cholesterol metabolism and heart disease prevention. Penn recently created a new Cardiovascular Institute that is charged with promoting translational research in the diagnosis, treatment, and prevention of cardiovascular disease. Additionally, Penn was recently awarded a large NIH grant to foster the further development of translational research under the auspices of the newly created Institute for Translational Medicine and Therapeutics.


The results of this study are in The New England Journal of Medicine. The article is titled "Inhibition of Microsomal Triglyceride Transfer Protein in Homozygous Familial Hypercholesterolemia." Co-authors from Penn: Marina Cuchel, MD, PhD; LeAnne T. Bloedon, MS, RD; Philippe O. Szapary, MD; Daniel M. Kolansky, MD; Megan L. Wolfe, BS; John S. Millar, PhD; Evan S. Siegelman, MD; and Daniel J. Rader, MD. Other researchers: Antoine Sarkis, MD, Hotel Dieu de France Hospital, St. Joseph University, Beirut, Lebanon; Katsunori Ikewaki, MD, Jikei University School of Medicine, Tokyo, Japan; and Richard E. Gregg, MD, from Bristol-Myers Squibb Pharmaceutical Research Institute, Lawrenceville, NJ.


This study was supported by a Distinguished Clinical Scientist Award (to Rader) from the Doris Duke Charitable Foundation and grants from the National Center for Research Resources.


Dr. Daniel Rader receives lecture fees, consulting fees, and grant support from Bristol Myers-Squibb, as well as from other companies that manufacture lipid-lowering drugs, and has equity interest in Aegerion Pharmaceuticals, which holds the license to develop BMS-201038. LeAnne Bloedon serves as a consultant for Aegerion Pharmaceuticals. Dr. Philippe Szapary is an employee of and has equity interest in Wyeth.


Daniel Rader, MD, Director of Preventive Cardiovascular Medicine and Lipid Clinic at Penn -- on-line bio: uphs.upenn/cardio/faculty/rader.html


For more information on Aegerion, visit:

aegerion


For more information on Bristol-Myers Squibb, visit:

bms


For more information on the Doris Duke Charitable Foundation, visit:

ddcf


PENN Medicine is a $2.9 billion enterprise dedicated to the related missions of medical education, biomedical research, and high-quality patient care. PENN Medicine consists of the University of Pennsylvania School of Medicine (founded in 1765 as the nation's first medical school) and the University of Pennsylvania Health System.


Penn's School of Medicine is ranked #2 in the nation for receipt of NIH research funds; and ranked #3 in the nation in U.S. News & World Report's most recent ranking of top research-oriented medical schools. Supporting 1,400 fulltime faculty and 700 students, the School of Medicine is recognized worldwide for its superior education and training > of the next generation of physician-scientists and leaders of academic medicine.


The University of Pennsylvania Health System includes three hospitals [Hospital of the University of Pennsylvania; Pennsylvania Hospital, the nation's first hospital; and Penn Presbyterian Medical Center]; a faculty practice plan; a primary-care provider network; two multispecialty satellite facilities; and home care and hospice.

Комментариев нет:

Отправить комментарий